Elicio Therapeutics, Inc.
For the period ended Mar 31, 2025. Filed May 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 13, 2025
ELTX$1.61-2.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows (unaudited)
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities | ||
| Net loss | $(11,209) | $(11,827) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 53 | 82 |
| Amortization of right-of-use assets, operating leases | 225 | 208 |
| Non-cash interest expense | 107 | — |
| Amortization of debt discount | 35 | — |
| Change in fair value of warrant liabilities | 507 | 1,278 |
| Stock-based compensation expense | 517 | 324 |
| Loss on issuance of warrants | — | 578 |
| Gain on disposal of property and equipment, net | — | (3) |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (4) | 1,085 |
| Other long-term prepaid assets | — | 160 |
| Accounts payable | 2,999 | (3,264) |
| Accrued expenses and other current liabilities | (2,645) | (432) |
| Deferred research obligation | (489) | (67) |
| Operating lease liabilities | (215) | (244) |
| Net cash used in operating activities | (10,119) | (12,122) |
| Cash flows from investing activities | ||
| Proceeds from sale of property and equipment | — | 3 |
| Net cash provided by investing activities | — | 3 |
| Cash flows from financing activities | ||
| Proceeds from exercise of common warrants | 343 | — |
| Proceeds from issuance of common stock and common warrants from the January Offering | 9,143 | — |
| Proceeds from issuance of common warrants | — | 5,962 |
| Proceeds from issuance of common stock | 835 | 5,062 |
| Proceeds from the exercise of stock options | 7 | — |
| Net cash provided by financing activities | 10,328 | 11,024 |
| Effect of foreign currency on cash | 31 | — |
| Net increase (decrease) in cash and cash equivalents | 240 | (1,095) |
| Cash, cash equivalents and restricted cash at the beginning of the period | 19,492 | 14,301 |
| Cash, cash equivalents and restricted cash at the end of the period | $19,732 | $13,206 |
| Components of cash, cash equivalents, and restricted cash | ||
| Cash and cash equivalents | $18,351 | $11,853 |
| Restricted cash | 1,381 | 1,353 |
| Total cash, cash equivalents and restricted cash | $19,732 | $13,206 |
| Supplemental disclosure of noncash investing and financing activities: | ||
| Fair value of pre-funded warrants at issuance date | $— | $6,579 |
| Fair value of common warrants upon settlement | $373 | $— |
| Conversion of related-party senior note payable into equity | $20,034 | $— |
| Non-cash vesting of restricted common stock | $— | $11 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.